Management: in Stability and Preservative Nano-sized colloidal suspension particles can undergo chemical degradation or aggregation

The gap

Evidence profile

Sourced from the future work and limitations of the source papers, classified as general, drawn from work published between 2024 and 2026, spanning 4 journals. Those papers have been cited 180 times in total.

Supporting evidence — 5 representative gaps

• Advancing biomedical applications: an in-depth analysis of silver nanoparticles in antimicrobial, anticancer, and wound healing roles (2024) · Frontiers in Pharmacology · cited 142× · doi

  As the scientific community delves deeper into the realm of silver nanoparticles (AgNPs), it becomes imperative to strategically in this assess both the challenges and opportunities inherent innovative field. The ensuing SWOT analysis serves as a crucial tool in dissecting the complexities and predicting the trajectory of AgNP research (Dhir et al., 2024). Challenges in this domain are multifaceted, with concerns such as potential cytotoxicity and the development of resistance taking precedence in scientific discourse. The economic viability of producing AgNPs on a large scale, compounded by a lack of comprehensive long-term safety data, further complicates their clinical and commercial applications. and Additionally, environmental ramifications of nanoparticle utilization necessitate thorough scrutiny and the adoption of sustainable practices. However, the future holds considerable promise for AgNPs, driven by the growing demand for advanced antimicrobial and anticancer therapies in healthcare. Advances in nanotechnology bolster the prospects for AgNPs, offering innovative applications through targeted drug delivery systems and synergistic therapeutic regulatory landscape evolving the

  generalfuture work
  Keywords: agnps scienti challenges innovative applications community delves deeper realm silver nanoparticles becomes imperative strategically assess
• The future for the therapeutics of abdominal aortic aneurysm: engineered nanoparticles drug delivery for abdominal aortic aneurysm (2024) · Frontiers in Bioengineering and Biotechnology · cited 13× · doi

  Presently, the clinical management of AAA predominantly revolves around surgical intervention, specifically for individuals at risk of AAA rupture and patients with large AAA. However, no pharmacological alternatives exist for patients who are unable to undergo surgery, and those experiencing ongoing AAA progression. Several studies have reported the advantages of drug-loaded engineered nanoparticles in the treatment of AAA, including the nanoparticles to increase the slow release and targeting of drugs, which can be localized in AAA at lower drug concentrations, showing good efficacy and safety. individuals with small AAA, However, challenges remain for further clinical translation. Firstly, some materials have high costs and long lead times to construct nanoparticles, and some show potential immunogenicity, or the constructed nanoparticles are so small that they can be quickly cleared in vivo. Secondly, when using antibody proteins to increase nanoparticle targeting, these antibodies are prone to denaturation during the construction process and may be degraded by a variety of enzymes in vivo, with loss of targeting. Finally, preclinical studies on nanoparticle drug delivery for AAA mainly focus on rodent models, which have shown exciting results. However, using only a single model cannot perfectly replace the pathogenic environment of AAA patients (e.g., pressure, flow rate, and composition of internal circulation), and further validation in multiple models is needed before entering clinical practice.

  generalfuture work
  Keywords: nanoparticles clinical patients drug targeting individuals increase small further vivo using nanoparticle models presently management
• Gemcitabine-Vitamin E Prodrug-Loaded Micelles for Pancreatic Cancer Therapy (2024) · Pharmaceutics · cited 17× · doi

  systems. delivery Pharm. 2021, drug 592, Int. 9. J. 10. Wen, P.; Ke, W.; Dirisala, A.; Toh, K.; Tanaka, M.; Li, J. Stealth and pseudo-stealth nanocarriers. Adv. Drug Deliv. Rev. 2023, 198, 114895. https://doi.org/10.1016/j.addr.2023.114895. 11. Li, J.; Kataoka, K. Chemo-physical Strategies to Advance the in Vivo Functionality of Targeted Nanomedicine: The Next Generation. J. Am. Chem. Soc. 2021, 143, 538–559. https://doi.org/10.1021/jacs.0c09029. 12. Cabral, H.; Miyata, K.; Osada, K.; Kataoka, K. Block Copolymer Micelles in Nanomedicine Applications. Chem. Rev. 2018, 118, 6844–6892. https://doi.org/10.1021/acs.chemrev.8b00199. 13. Wang, J.; Zhang, X.; Cen, Y.; Lin, X.; Wu, Q. Antitumor gemcitabine conjugated micelles from amphiphilic comb-like random copolymers. Colloids Surf. B Biointerfaces 2016, 146, 707–715. https://doi.org/10.1016/j.colsurfb.2016.07.027. 14. Coppens, E.; Desmaele, D.; Mougin, J.; Tusseau-Nenez, S.; Couvreur, P.; Mura, S. Gemcitabine Lipid Prodrugs: The Key Role of 782–793. into Nanoparticles. Bioconjugate Chem. Self-Assembly 2021, 32, the Lipid Moiety https://doi.org/10.1021/acs.bioconjchem.1c00051. the on 15. Emamzadeh, M.; Desmaele, D.; Couvreur, P.; Pasparakis, G. Dual controlled delivery of squalenoyl-gemcitabine and paclitaxel J. Mater. Chem. B 2018, 6, 2230–2239. thermo-responsive polymeric micelles for pancreatic cancer. using https://doi.org/10.1039/c7tb02899g. 16. Jin, Y.; Lian, Y.; Du, L.; Wang, S.; Su, C.; Gao, C. Self-assembled drug delivery systems. Part 6: In vitro/in vivo studies of 276–281. nanoassemblies. gemcitabine Pharm. 2012, 430, Int. J. anticancer N-octadecanoyl https://doi.org/10.1016/j.ijpharm.2012.03.046. 17. Jin, Y.; Lian, Y.; Du, L. Self-assembly of N-acyl derivatives of gemcitabine at the air/water interface and the formation of 60–65. Physicochem.

  generalfuture work
  Keywords: https gemcitabine chem delivery drug micelles self systems pharm stealth kataoka vivo nanomedicine wang desmaele
• Advances in Gold Nanoparticles for the Diagnosis and Management of Alzheimer’s Disease (2025) · Pharmaceutics · cited 8× · doi

  Exploring the current limitations and future perspectives of AuNP-based interventions for AD offers valuable insights into refining strategies and unlocking their full therapeutic potential in clinical applications. Current clinical therapy for AD primarily aims to manage symptoms and provide supplementary brain nutrition, offering comfort care without ad- dressing the underlying cause of the disease [101]. The complications of AD pathology and the difficulties in delivering drugs beyond the BBB are the major limitations to managing AD effectively. Nanocarriers have garnered attention owing to their exceptional biocompat- ibility, stability, degradability, flexible drug-loading methods, safety, surface modifiability, and controllable drug release. They are interesting candidates for directed treatment for AD and other CNS diseases. However, commercial production of nanomedicine remains a significant challenge. The BBB, comprising pericytes, astrocytes, capillary basement membrane, and endothelial cells, acts as a protective barrier, limiting the entry of definite molecules or pathogens from the circulatory system into the brain [126]. The capabil- ity of nanomedicine in treating neurodegenerative diseases is immense. Although some nanomedicines are undergoing clinical trials for AD, none have been approved yet. Most nanomedicine research is currently in the preclinical stage [127]. The research must prioritize overcoming BBB-related barriers and enhancing drug delivery systems, thereby advancing the field of nanomedicine and facilitating the de- velopment of more efficient treatments for AD and other CNS diseases [101]. Further investigation into the physicochemical properties of AuNPs is warranted to deepen our understanding and potentially leverage their effects for therapeutic purposes [76]. Ad- ditionally, the limited understanding of the physiological and pathological mechanisms underlying AD poses a challenge to developing efficient nanomaterial-based treatments. If the fundamental biological mechanism of AD is revealed, nanomaterial-based treatments are expected to play an increasingly significant role in its treatment [101].

  generalfuture work
  Keywords: nanomedicine based clinical drug diseases treatments current limitations therapeutic brain underlying treatment significant challenge efficient
• Nanotechnology-Driven Drug Delivery System: Recent Advances, Applications and Future Perspectives (2026) · Journal of Drug Delivery and Therapeutics · doi

  Management: in Stability and Preservative Nano-sized colloidal suspension particles can undergo chemical degradation or aggregation during product preservation, which may also change their size and effectiveness of the product9. 4. Compliance and Ethical Barriers: As nanotechnology-based drugs are recently developed, compliance requirements their authorisation, evaluation, and safety assessment are still progressing. This endures their path from laboratory research to medicinal use6. for ISSN: 2250-1177 CODEN (USA): JDDTAO Chandola et al. Journal of Drug Delivery & Therapeutics. 2026; 16(4):185-194 5. Restricted Follow-up Data: Mostly, the nano-scale based medical procedures are still initial clinical studies. Their under evaluation or prolonged effects on organs, biotransformation, and the immunological system are not yet clearly understood7.

  generallimitationsevidence 5/5
  Keywords: nano product compliance nanotechnology based evaluation still advantages management stability preservative sized colloidal suspension particles

Questions about this gap